Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.
Amarin’s fish oil formulation Vascepa impressed on hard cardiovascular endpoints, but there is confusion about worsening cholesterol in the placebo group.
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.